BACKGROUND: Levetiracetam (Keppra) is a novel antiepileptic drug recently approved by the U.S. Food and Drug Administration as an add-on therapy in the treatment of partial onset seizures in patients. We developed and describe a simple and rapid high performance liquid chromatography-electrospray tandem mass spectrometry (HPLC-ESI-MS/MS) assay for the determination of levetiracetam in human matrix (plasma, serum, or saliva). METHODS: An API-3000 or API-4000 triple-quadrupole mass spectrometer (Sciex, Concord, Canada) coupled with the IonSpray source and Shimadzu HPLC system (Shimadzu Scientific Instruments, Columbia, MD) was used employing ritonavir as internal standard (IS) for levetiracetam. One hundred microliters of serum (or plasma, saliva) was deproteinized by adding 150 microl of acetonitrile containing internal standard. After centrifugation, 100 microl of supernatant was diluted with 300 microl of water and 10 microl aliquot was injected onto a C-18 column. After a 2.5 min wash the valve was activated to initiate the isocratic elution program which eluted the levetiracetam and internal standard into the MS/MS system. Quantitation by MRM analysis was performed in the positive ion mode. Within-day and between-day imprecision were evaluated for levetiracetam using three levels of in-house controls. Reliability and accuracy of this method were assessed by comparison of targets with external QC material (ChromSystems), between laboratory comparisons and by recovery studies. RESULTS: Within-day coefficients of variation (CVs) were <6.1% and between-day CVs were <8.2%. The average spiked recoveries of levetiracetam added to the drug-free human plasma samples were 108% at low concentration level and 103% at high concentration level. CONCLUSIONS: The method was found both specific and sensitive for the rapid and accurate measurement of levetiracetam in human matrices and correlated well with the Quest/Chantilly tandem mass spectrometric method (r=0.983).
BACKGROUND:Levetiracetam (Keppra) is a novel antiepileptic drug recently approved by the U.S. Food and Drug Administration as an add-on therapy in the treatment of partial onset seizures in patients. We developed and describe a simple and rapid high performance liquid chromatography-electrospray tandem mass spectrometry (HPLC-ESI-MS/MS) assay for the determination of levetiracetam in human matrix (plasma, serum, or saliva). METHODS: An API-3000 or API-4000 triple-quadrupole mass spectrometer (Sciex, Concord, Canada) coupled with the IonSpray source and Shimadzu HPLC system (Shimadzu Scientific Instruments, Columbia, MD) was used employing ritonavir as internal standard (IS) for levetiracetam. One hundred microliters of serum (or plasma, saliva) was deproteinized by adding 150 microl of acetonitrile containing internal standard. After centrifugation, 100 microl of supernatant was diluted with 300 microl of water and 10 microl aliquot was injected onto a C-18 column. After a 2.5 min wash the valve was activated to initiate the isocratic elution program which eluted the levetiracetam and internal standard into the MS/MS system. Quantitation by MRM analysis was performed in the positive ion mode. Within-day and between-day imprecision were evaluated for levetiracetam using three levels of in-house controls. Reliability and accuracy of this method were assessed by comparison of targets with external QC material (ChromSystems), between laboratory comparisons and by recovery studies. RESULTS: Within-day coefficients of variation (CVs) were <6.1% and between-day CVs were <8.2%. The average spiked recoveries of levetiracetam added to the drug-free human plasma samples were 108% at low concentration level and 103% at high concentration level. CONCLUSIONS: The method was found both specific and sensitive for the rapid and accurate measurement of levetiracetam in human matrices and correlated well with the Quest/Chantilly tandem mass spectrometric method (r=0.983).
Authors: Pavel Klein; Daniel Herr; Phillip L Pearl; JoAnne Natale; Zachary Levine; Claude Nogay; Fabian Sandoval; Stacey Trzcinsky; Shireen M Atabaki; Tammy Tsuchida; John van den Anker; Steven J Soldin; Jianping He; Robert McCarter Journal: Epilepsy Behav Date: 2012-07-07 Impact factor: 2.937
Authors: Emil Vinţeler; Nicoleta-Florina Stan; Raluca Luchian; Călin Căinap; João P Prates Ramalho; Vasile Chiş Journal: J Mol Model Date: 2015-03-13 Impact factor: 1.810
Authors: Stephanie L Merhar; Kurt R Schibler; Catherine M Sherwin; Jareen Meinzen-Derr; Jing Shi; Tonya Balmakund; Alexander A Vinks Journal: J Pediatr Date: 2011-05-18 Impact factor: 4.406
Authors: Helena A Soini; Iveta Klouckova; Donald Wiesler; Elisabeth Oberzaucher; Karl Grammer; Sarah J Dixon; Yun Xu; Richard G Brereton; Dustin J Penn; Milos V Novotny Journal: J Chem Ecol Date: 2010-08-31 Impact factor: 2.626
Authors: Elizabeth Greiner-Sosanko; Spiros Giannoutsos; Darla R Lower; Mohamed A Virji; Matthew D Krasowski Journal: J Chromatogr Sci Date: 2007-10 Impact factor: 1.618